Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease
A Randomized, Double-Blind, Placebo-Controlled Evaluation of Single Doses of PF-07209326 in Healthy Participants (Safety, Tolerability, and Pharmacokinetics [PK]) Followed by an Open-Label, Repeat Dose Evaluation in Sickle Cell Disease Participants (Safety, Tolerability, PK and Efficacy)
Category & Conditions: Rare Diseases
Medicine: PF-07209326
ClinicalTrials.gov Identifier (NCT): NCT04255875
Protocol ID: C4071001
Open Plain Language Summary Result:
Click here